Washington, DC – In a significant victory for seniors and patients facing high medication costs, New Jersey District Court Judge Zahid Quraishi dismissed Novo Nordisk’s challenge to the Inflation Reduction Act, thwarting the pharmaceutical company’s efforts to prevent Medicare from negotiating lower drug prices with manufacturers.

“Despite repeated setbacks, big pharma relentlessly targets seniors and patients who struggle to afford essential medications by opposing the Biden-Harris administration’s historic Medicare negotiation initiative,” stated Tony Carrk, Executive Director of Accountable.US. “They are flooding the courts to stop seniors from saving billions annually to maintain their own profits, but the public is weary of exorbitant drug prices.”

This latest decision marks the sixth time a federal court has upheld Medicare’s authority to negotiate drug prices. However, pharmaceutical companies are ramping up their legal battles to obstruct the Biden-Harris administration’s efforts to reduce drug costs for Americans. A recent analysis by government watchdog Accountable.US revealed that several special interest groups, which filed amicus briefs supporting pharmaceutical giants AstraZeneca, Bristol Myers Squibb, and Janssen in the U.S. Court of Appeals for the Third Circuit, have received nearly $4.8 million from PhRMA since 2019